Chemotherapy
| . | Dose . | Schedule . |
|---|---|---|
| Age < 60 y | ||
| Induction | Daunorubicin 45 mg/m2 IV | d 1-3 |
| ARA-C 100 mg/m2 CI | d 1-7 | |
| HIDAC 2 g/m2 IV over 90 min | 6 doses, every 12 h; d 8-10 | |
| Consolidation (3 cycles) | ARA-C 3 g/m2 over 3 h | 6 doses, every 12 h; d 1, 3, 5 |
| Age ≥ 60 y | ||
| Induction | Daunorubicin 45 mg/m2 IV | d 1-3 |
| ARA-C 200 mg/m2 CI | d 1-7 | |
| Consolidation | ARA-C 1.5 g/m2 over 2 h | 8 doses, every 12 h |
| . | Dose . | Schedule . |
|---|---|---|
| Age < 60 y | ||
| Induction | Daunorubicin 45 mg/m2 IV | d 1-3 |
| ARA-C 100 mg/m2 CI | d 1-7 | |
| HIDAC 2 g/m2 IV over 90 min | 6 doses, every 12 h; d 8-10 | |
| Consolidation (3 cycles) | ARA-C 3 g/m2 over 3 h | 6 doses, every 12 h; d 1, 3, 5 |
| Age ≥ 60 y | ||
| Induction | Daunorubicin 45 mg/m2 IV | d 1-3 |
| ARA-C 200 mg/m2 CI | d 1-7 | |
| Consolidation | ARA-C 1.5 g/m2 over 2 h | 8 doses, every 12 h |
IV indicates intravenous; CI indicates continuous infusion.